In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.
A single oral dose of rimegepant offers rapid, sustained pain relief for the acute treatment of migraine, thus allowing early return to normal function without the need for repeat dosing or rescue medications, results of three phase III studies presented at the AHS 2020 Meeting have shown.
Ubrogepant sustains its favourable effect for migraine regardless of demographic and clinical features, and concomitant medication use, according to pooled results of the ACHIEVE I and II studies presented at AHS 2020.
Long-term use of onabotulinumtoxinA led to reductions in monthly headache days (MHDs) in adults with chronic migraine (CM), according to post hoc analyses of the COMPEL* study presented at the AHS 2020 virtual scientific meeting.
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Obesity does not appear to be strongly correlated with an increased risk for febrile neutropaenia during levofloxacin prophylaxis in patients with haematological malignancies receiving intermediate-risk myelosuppressive chemotherapy, suggests a study.
Initiation or switch to the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (TAF) led to low HIV-1 RNA viral load in people living with HIV (PLHIV), according to the BICSTaR study presented at HIV Glasgow 2020.
Use of corticosteroids appears to be an effective treatment for paediatric drug reaction with eosinophilia and systemic symptoms (DRESS), suggest the results of a recent study. In severe cases, corticosteroids used in conjunction with intravenous immunoglobulin result in fast clinical improvement.
Patients with chronic obstructive pulmonary disease (COPD) seem to benefit from using chlorhexidine oral rinses twice daily as shown by the reduction in oral and sputum microbiota alpha diversity and by clinically significant improvements in COPD symptoms, according to a study presented at ID Week 2020.